PReS13-SPK-1028: Activity and damage - we have to measure them
نویسندگان
چکیده
منابع مشابه
PReS13-SPK-1028: Activity and damage - we have to measure them
Background Childhood-onset SLE is a complex multiorgan disease. In order to judge the need of medical intervnetions and the patient benefits from them, measurement disease activity and damage are key. Furthermore, important improvement and deterioration of disease needs to be ascertained. Such measurement are the basis for clinical trial aimed at identifying improved medications and are needed ...
متن کاملPReS13-SPK-1247: Activity and damage in juvenile systemic sclerosis- we have to measure them
Juvenile systemic sclerosis (jSSc) is an orphan disease. There are no established activity and damage indices fort the juvenile form. In the adult form the are prospective studies aiming to validate the activity and damage indices. The assessment of the activity and damage is important in jSSc too to be able to stage the severity of the disease, judge the response to the therapy. One of the mai...
متن کاملPReS13-SPK-1582: Activity and damage - we have to measure them
“You can’t manage what you don’t measure.” The world community–led by the IMACS and PRINTO groups–has developed robust core criteria to measure disease activity and damage for Juvenile Dermatomyositis studies. These measures are tremendously useful in clinical practice, and not just for research. More problematic has been determining clinically meaningful change. The current definitions of chan...
متن کاملPReS13-SPK-1469: Juvenile scleroderma
Juvenile localized scleroderma, also known as morphea, is the more frequent subtype of scleroderma in childhood. It comprises a group of distinct conditions which involve the skin and subcutaneous tissues. They range from very small plaques of fibrosis involving only the skin, to diseases which may cause significant functional and cosmetic deformity. The most widely used classification divides ...
متن کاملPReS13-SPK-1587: New biologic targets for the future and basic science behind them
The treatment of paediatric rheumatic diseases has made great progress in the last decade. The introduction of the biologicals meant (after the introduction of MTX) the second therapeutic revolution. This together with many improvements in related areas has greatly improved the quality of life of patients with rheumatic diseases. At present however, despite the introduction of more biological a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s2-i22